Bicycle Therapeutics PLC (BCYC) shareholders
Close on Nov 17, 2026Market cap $224.30MP/E –Yield 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Felix J. Baker Joint filing with Baker Bros. Advisors LP (22.90%), Baker Bros. Advisors (GP) LLC (22.90%) and 1 more | 10,885,357 | 22.90% | 13D (active) amendment | Dec 13, 2024 |
| Point72 Capital Advisors, Inc. Joint filing with Point72 Asset Management, L.P. (8.90%), Steven A. Cohen (8.90%) | 4,230,302 | 8.90% | 13G (passive) | Dec 13, 2024 |
| Steven A. Cohen Joint filing with Point72 Asset Management, L.P. (7.80%), Point72 Capital Advisors, Inc. (7.80%) | 3,739,318 | 7.80% | 13G (passive) amendment | Mar 31, 2025 |
| Forbion Growth Ii Management B.V. Joint filing with Forbion Growth Opportunities Fund II Cooperatief U.A. (7.30%) | 3,452,330 | 7.30% | 13G (passive) | Nov 21, 2024 |
| Armistice Capital, LLC Joint filing with Steven Boyd (6.75%) | 3,398,000 | 6.75% | 13G (passive) amendment | Mar 31, 2026 |
| Steven Boyd Joint filing with Armistice Capital, LLC (6.72%) | 3,398,000 | 6.72% | 13G (passive) amendment | Jun 30, 2026 |
| John Helmers Joint filing with Long Focus Capital Management, LLC (6.60%) | 3,310,687 | 6.60% | 13G (passive) | Mar 31, 2026 |
| David Kroin Joint filing with Deep Track Capital, LP (5.67%), Deep Track Biotechnology Master Fund, Ltd. (5.67%) | 2,821,171 | 5.67% | 13G (passive) amendment | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BCYC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 10,885,357 | 15.53% | $46.15M | – | 0.23% |
| Fcpm Iii Services B.V. | 3,468,430 | 4.95% | $14.71M | – | 1.96% |
| Armistice Capital, LLC | 3,398,000 | 4.85% | $14.41M | – | 0.18% |
| Long Focus Capital Management, LLC | 3,310,687 | 4.72% | $14.04M | – | 0.36% |
| Acadian Asset Management LLC | 1,968,025 | 2.81% | $8.32M | – | 0.01% |
| Renaissance Technologies LLC | 1,533,400 | 2.19% | $6.50M | +554,100 | 0.01% |
| GSK plc | 1,529,561 | 2.18% | $6.49M | – | 1.08% |
| Price T Rowe Associates Inc /Md/ | 902,150 | 1.29% | $3.83M | −126,093 | 0.00% |
| Marshall Wace, Llp | 797,940 | 1.14% | $3.38M | +420,605 | 0.00% |
| Qube Research & Technologies Ltd | 775,567 | 1.11% | $3.29M | +466,950 | 0.00% |
| Morgan Stanley | 667,269 | 0.95% | $2.83M | +48,942 | 0.00% |
| Schroder Investment Management Group | 615,833 | 0.88% | $2.56M | – | 0.00% |
| Citadel Advisors LLC | 554,225 | 0.79% | $2.35M | +177,140 | 0.00% |
| Millennium Management LLC | 553,967 | 0.79% | $2.35M | +269,981 | 0.00% |
| Peapod Lane Capital LLC | 537,978 | 0.77% | $2.28M | +416,872 | 1.54% |
| Diadema Partners LP | 462,724 | 0.66% | $1.96M | −13,700 | 0.25% |
| Two Sigma Investments, LP | 434,577 | 0.62% | $1.84M | +269,777 | 0.00% |
| Jane Street Group, LLC | 392,163 | 0.56% | $1.66M | +174,048 | 0.00% |
| Flax Pond Capital, LLC | 376,222 | 0.54% | $1.67M | +200,086 | 0.62% |
| Birchview Capital, LP | 313,616 | 0.45% | $1.33M | −149,983 | 0.62% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 104 | 37M | 53.4% | 19 / 34 | 18 / 13 | 4M | 4M |
| Q1 2026 | 98 | 37M | 53.4% | 15 / 43 | 16 / 26 | 5M | 7M |
| Q4 2025 | 109 | 39M | 55.9% | 22 / 35 | 29 / 11 | 5M | 3M |
| Q3 2025 | 99 | 37M | 52.7% | 10 / 38 | 24 / 21 | 3M | 7M |
| Q2 2025 | 110 | 41M | 58.8% | 29 / 38 | 20 / 14 | 5M | 5M |
| Q1 2025 | 95 | 42M | 59.5% | 15 / 28 | 30 / 17 | 4M | 4M |
| Q4 2024 | 97 | 42M | 59.8% | 16 / 29 | 36 / 23 | 11M | 10M |
| Q3 2024 | 105 | 40M | 57.7% | 17 / 34 | 33 / 18 | 6M | 5M |
| Q2 2024 | 107 | 40M | 57.5% | 26 / 35 | 25 / 14 | 16M | 9M |
| Q1 2024 | 95 | 34M | 47.9% | 13 / 29 | 33 / 17 | 8M | 7M |
| Q4 2023 | 101 | 33M | 47.0% | 21 / 37 | 30 / 21 | 8M | 7M |
| Q3 2023 | 101 | 32M | 46.3% | 24 / 35 | 24 / 7 | 10M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
26 funds held BCYC in Q1 2026, 12% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of BCYC | Value | % of fund | As of |
|---|---|---|---|---|---|
| T. Rowe Price Health Sciences Fund, Inc. | 628,421 | 0.90% | $2.66M | 0.02% | Jun 30, 2026 |
| Old Westbury Small & Mid Cap Strategies Fund | 265,973 | 0.38% | $1.03M | 0.01% | Jul 31, 2026 |
| iShares Biotechnology ETF | 242,577 | 0.35% | $1.03M | 0.01% | Jun 30, 2026 |
| Virtus Biotech Clinical Trials Etf | 76,743 | 0.11% | $296.23K | 0.64% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Portfolio | 62,846 | 0.09% | $266.47K | 0.04% | Jun 30, 2026 |
| ALPS Medical Breakthroughs ETF | 51,450 | 0.07% | $241.30K | 0.15% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) International Small Cap ETF | 30,829 | 0.04% | $130.71K | 0.02% | Jun 30, 2026 |
| Voya Multi-Manager International Small Cap Fund | 30,052 | 0.04% | $116.00K | 0.02% | Jul 31, 2026 |
| Health Sciences Trust | 25,602 | 0.04% | $108.55K | 0.04% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 25,129 | 0.04% | $117.86K | 0.00% | May 31, 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 13,410 | 0.02% | $62.89K | 0.33% | May 31, 2026 |
| Horizon Kinetics Medical ETF | 12,584 | 0.02% | $53.36K | 0.28% | Jun 30, 2026 |
| Steward Values Enhanced International Fund | 11,209 | 0.02% | $43.27K | 0.01% | Jul 31, 2026 |
| EQ/T.Rowe Price Health Sciences Portfolio | 9,600 | 0.01% | $40.70K | 0.02% | Jun 30, 2026 |
| Harbor International Core Fund | 6,102 | 0.01% | $23.55K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Kevin Lee | CHIEF EXECUTIVE OFFICER, Director | 595,866 | 0.85% | Oct 6, 2026 |
| Jennifer Scott Perry | Chief Operating Officer | 89,602 | 0.13% | Oct 7, 2026 |
| Michael Skynner | CHIEF SCIENTIFIC OFFICER | 154,726 | 0.22% | Oct 6, 2026 |
| Michael Charles Ferguson Hannay | CHIEF PROD & SUPPLY CHAIN OFF | 92,561 | 0.13% | Oct 6, 2026 |
| Travis Alvin Thompson | Chief Financial Officer | 64,449 | 0.09% | Oct 6, 2026 |
| Alistair Milnes | CHIEF OPERATING OFFICER | 136,717 | 0.20% | Jan 6, 2026 |
| Alethia Young | Chief Financial Officer | 88,959 | 0.13% | Jan 6, 2026 |
| Eric Westin | Chief Medical Officer | 2,305 | 0.00% | Mar 27, 2025 |
| Nigel Crockett | CHIEF BUSINESS OFFICER | 51,053 | 0.07% | Jan 6, 2025 |
| Santiago Arroyo | CHIEF DEVELOPMENT OFFICER | 69,057 | 0.10% | Jan 6, 2025 |
| Robert Charles Swanton | Director | 15,782 | 0.02% | Oct 6, 2026 |
| Roger D. Dansey | Director | 15,532 | 0.02% | Jan 6, 2026 |
| Stephen H. Sands | Director | 26,893 | 0.04% | Jan 6, 2026 |
| Jose-Carlos Gutierrez-Ramos | Director | 32,500 | 0.05% | Jan 6, 2026 |
| Bros. Advisors Lp Baker | Director, 10% owner | 918,483 | 1.31% | Jan 6, 2026 |
| Julian Baker | Director, 10% owner | – | – | Jan 6, 2026 |
| Felix Baker | Director, 10% owner | 937,483 | 1.34% | Jan 6, 2026 |
| Brothers Life Sciences LP Baker | Director, 10% owner | 579,856 | 0.83% | Jan 6, 2026 |
| Bros. Advisors (GP) LLC Baker | Director, 10% owner | 9,995,274 | 14.26% | Jan 6, 2026 |
| 667, L.P. | Director, 10% owner | 787,954 | 1.12% | Jan 6, 2026 |
| Herve Hoppenot | Director | 15,532 | 0.02% | Jan 6, 2026 |
| Gregory Paul Winter | Director | 196,427 | 0.28% | Jan 6, 2026 |
| Janice Bourque | Director | 32,500 | 0.05% | Jan 6, 2026 |
| Alessandro Riva | Director | 19,880 | 0.03% | Jan 6, 2026 |
| Pierre Legault | Director | 46,000 | 0.07% | Jan 6, 2025 |
| Richard N. Kender | Director | 23,000 | 0.03% | Jan 6, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jennifer Scott Perry Chief Operating Officer | Oct 5, 2026 | Sale(10b5-1 plan) | −326 | $3.78 | $1.23K | 89,602 |
| Jennifer Scott Perry Chief Operating Officer | Oct 5, 2026 | Sale(10b5-1 plan) | −30 | $3.57 | $107 | 89,928 |
| Jennifer Scott Perry Chief Operating Officer | Oct 5, 2026 | Sale(10b5-1 plan) | −326 | $3.78 | $1.23K | 89,552 |
| Jennifer Scott Perry Chief Operating Officer | Oct 5, 2026 | Sale(10b5-1 plan) | −80 | $3.56 | $285 | 89,878 |
| Michael Charles Ferguson Hannay CHIEF PROD & SUPPLY CHAIN OFF | Oct 5, 2026 | Sale | −242 | $3.57 | $864 | 92,561 |
| Travis Alvin Thompson Chief Financial Officer | Oct 5, 2026 | Sale | −79 | $3.57 | $282 | 64,449 |
| Kevin Lee CHIEF EXECUTIVE OFFICER, Director | Oct 5, 2026 | Sale | −1,638 | $3.57 | $5.85K | 595,866 |
| Michael Skynner CHIEF SCIENTIFIC OFFICER | Oct 5, 2026 | Sale | −503 | $3.57 | $1.80K | 154,726 |
| Jennifer Scott Perry Chief Operating Officer | Oct 2, 2026 | Sale(10b5-1 plan) | −1,094 | $3.47 | $3.80K | 89,958 |
| Robert Charles Swanton Director | Oct 2, 2026 | Sale | −3,431 | $3.47 | $11.91K | 15,782 |
| Michael Charles Ferguson Hannay CHIEF PROD & SUPPLY CHAIN OFF | Oct 2, 2026 | Sale | −1,572 | $3.47 | $5.45K | 92,803 |
| Travis Alvin Thompson Chief Financial Officer | Oct 2, 2026 | Sale | −893 | $3.47 | $3.10K | 64,528 |
| Kevin Lee CHIEF EXECUTIVE OFFICER, Director | Oct 2, 2026 | Sale | −6,167 | $3.47 | $21.40K | 597,504 |
| Michael Skynner CHIEF SCIENTIFIC OFFICER | Oct 2, 2026 | Sale | −1,942 | $3.47 | $6.74K | 155,229 |
| Travis Alvin Thompson Chief Financial Officer | Jul 6, 2026 | Sale | −104 | $4.31 | $448 | 64,441 |
| Jennifer Scott Perry Chief Operating Officer | Jul 6, 2026 | Sale(10b5-1 plan) | −43 | $4.31 | $185 | 91,385 |
| Jennifer Scott Perry Chief Operating Officer | Jul 6, 2026 | Sale(10b5-1 plan) | −333 | $4.34 | $1.45K | 91,052 |
| Kevin Lee CHIEF EXECUTIVE OFFICER, Director | Jul 6, 2026 | Sale | −1,737 | $4.31 | $7.49K | 603,671 |
| Michael Skynner CHIEF SCIENTIFIC OFFICER | Jul 6, 2026 | Sale | −532 | $4.31 | $2.29K | 157,171 |
| Michael Charles Ferguson Hannay CHIEF PROD & SUPPLY CHAIN OFF | Jul 6, 2026 | Sale | −255 | $4.31 | $1.10K | 94,375 |
| Travis Alvin Thompson Chief Financial Officer | Jul 2, 2026 | Sale | −819 | $4.27 | $3.50K | 64,545 |
| Jennifer Scott Perry Chief Operating Officer | Jul 2, 2026 | Sale(10b5-1 plan) | −1,036 | $4.27 | $4.42K | 91,428 |
| Kevin Lee CHIEF EXECUTIVE OFFICER, Director | Jul 2, 2026 | Sale | −5,905 | $4.27 | $25.21K | 605,408 |
| Michael Skynner CHIEF SCIENTIFIC OFFICER | Jul 2, 2026 | Sale | −1,859 | $4.27 | $7.94K | 157,703 |
| Michael Charles Ferguson Hannay CHIEF PROD & SUPPLY CHAIN OFF | Jul 2, 2026 | Sale | −1,506 | $4.27 | $6.43K | 94,630 |
| Jennifer Scott Perry Chief Operating Officer | Apr 6, 2026 | Sale(10b5-1 plan) | −333 | $5.04 | $1.68K | 92,464 |
| Jennifer Scott Perry Chief Operating Officer | Apr 6, 2026 | Sale(10b5-1 plan) | −37 | $5.05 | $187 | 92,797 |
| Michael Skynner CHIEF SCIENTIFIC OFFICER | Apr 6, 2026 | Sale | −525 | $5.05 | $2.65K | 159,562 |
| Travis Alvin Thompson Chief Financial Officer | Apr 6, 2026 | Sale | −102 | $5.05 | $515 | 65,364 |
| Michael Charles Ferguson Hannay CHIEF PROD & SUPPLY CHAIN OFF | Apr 6, 2026 | Sale | −251 | $5.05 | $1.27K | 96,136 |
| Kevin Lee CHIEF EXECUTIVE OFFICER, Director | Apr 6, 2026 | Sale | −1,716 | $5.05 | $8.67K | 611,313 |
| Jennifer Scott Perry Chief Operating Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −1,038 | $4.91 | $5.10K | 92,834 |
| Michael Skynner CHIEF SCIENTIFIC OFFICER | Apr 2, 2026 | Sale | −1,879 | $4.91 | $9.23K | 160,087 |
| Travis Alvin Thompson Chief Financial Officer | Apr 2, 2026 | Sale | −799 | $4.91 | $3.92K | 65,466 |
| Michael Charles Ferguson Hannay CHIEF PROD & SUPPLY CHAIN OFF | Apr 2, 2026 | Sale | −1,521 | $4.91 | $7.47K | 96,387 |
| Kevin Lee CHIEF EXECUTIVE OFFICER, Director | Apr 2, 2026 | Sale | −5,967 | $4.91 | $29.30K | 613,029 |
| Kevin Lee CHIEF EXECUTIVE OFFICER, Director | Jan 5, 2026 | Sale | −10,989 | $6.46 | $70.99K | 618,996 |
| Michael Charles Ferguson Hannay CHIEF PROD & SUPPLY CHAIN OFF | Jan 5, 2026 | Sale | −2,367 | $6.45 | $15.27K | 97,908 |
| Alethia Young Chief Financial Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −2,456 | $6.45 | $15.84K | 88,959 |
| Alethia Young Chief Financial Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −1,878 | $6.54 | $12.28K | 87,081 |
| Alistair Milnes CHIEF OPERATING OFFICER | Jan 5, 2026 | Sale | −3,416 | $6.46 | $22.07K | 136,717 |
| Michael Skynner CHIEF TECHNOLOGY OFFICER | Jan 5, 2026 | Sale | −3,266 | $6.46 | $21.10K | 161,966 |
| Travis Alvin Thompson CHIEF ACCOUNTING OFFICER | Jan 5, 2026 | Sale | −1,115 | $6.45 | $7.19K | 66,265 |
| Alessandro Riva Director | Jan 2, 2026 | Award | +7,380 | – | – | 19,880 |
| Kevin Lee CHIEF EXECUTIVE OFFICER, Director | Jan 2, 2026 | Award | +165,000 | – | – | 640,310 |
| Kevin Lee CHIEF EXECUTIVE OFFICER, Director | Jan 2, 2026 | Sale | −10,325 | $6.80 | $70.21K | 629,985 |
| Michael Charles Ferguson Hannay CHIEF PROD & SUPPLY CHAIN OFF | Jan 2, 2026 | Sale | −2,827 | $6.80 | $19.22K | 100,275 |
| Michael Charles Ferguson Hannay CHIEF PROD & SUPPLY CHAIN OFF | Jan 2, 2026 | Award | +50,000 | – | – | 103,102 |
| Alethia Young Chief Financial Officer | Jan 2, 2026 | Award | +50,000 | – | – | 94,704 |
| Alethia Young Chief Financial Officer | Jan 2, 2026 | Sale(10b5-1 plan) | −3,289 | $6.80 | $22.37K | 91,415 |
| Roger D. Dansey Director | Jan 2, 2026 | Award | +3,032 | – | – | 15,532 |
| Jose-Carlos Gutierrez-Ramos Director | Jan 2, 2026 | Award | +9,500 | – | – | 32,500 |
| Stephen H. Sands Director | Jan 2, 2026 | Award | +9,500 | – | – | 26,893 |
| Janice Bourque Director | Jan 2, 2026 | Award | +9,500 | – | – | 32,500 |
| Alistair Milnes CHIEF OPERATING OFFICER | Jan 2, 2026 | Award | +50,000 | – | – | 143,377 |
| Alistair Milnes CHIEF OPERATING OFFICER | Jan 2, 2026 | Sale | −3,244 | $6.80 | $22.06K | 140,133 |
| Herve Hoppenot Director | Jan 2, 2026 | Award | +3,032 | – | – | 15,532 |
| Felix Baker Director, 10% owner | Jan 2, 2026 | Award | +19,000 | – | – | 937,483 |
| Felix Baker Director, 10% owner | Jan 2, 2026 | Award | +19,000 | – | – | 10,018,674 |
| Michael Skynner CHIEF TECHNOLOGY OFFICER | Jan 2, 2026 | Award | +50,000 | – | – | 168,277 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Bicycle Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 17,319 shares on Oct 7, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Kevin Lee Officer | Oct 2, 2026 | 9,000 | $31.23K | Oct 2, 2026 | Restricted Stock Units |
| Kevin Lee Officer | Jul 2, 2026 | 8,000 | $34.16K | Jul 2, 2026 | Restricted Stock Units |
| Kevin Lee Officer | Apr 2, 2026 | 8,000 | $39.24K | Apr 2, 2026 | Restricted Stock |
| Michael Skynner Officer | Apr 2, 2026 | 2,500 | $12.26K | Apr 2, 2026 | Restricted Stock |
| Alistair Milnes Officer | Apr 2, 2026 | 2,850 | $13.98K | Apr 2, 2026 | Restricted Stock |
| Michael Charles Ferguson Hannay Officer | Apr 2, 2026 | 1,850 | $9.07K | Apr 2, 2026 | Restricted Stock |
| Travis Alvin Thompson Officer | Apr 2, 2026 | 1,000 | $4.91K | Apr 2, 2026 | Restricted Stock |
| Alethia Young Officer | Apr 2, 2026 | 2,034 | $9.98K | Apr 2, 2026 | Restricted Stock |
| Jennifer Scott Perry Officer | Apr 2, 2026 | 1,500 | $7.36K | Apr 2, 2026 | Restricted Stock |
| Alethia Young Officer | Jan 5, 2026 | 123 | $803 | Jan 5, 2026 | Restricted Stock Units |
| Michael Skynner Officer | Jan 2, 2026 | 6,400 | $43.51K | Jan 2, 2026 | Restricted Stock Units |
| Alistair Milnes Officer | Jan 2, 2026 | 6,750 | $46.85K | Jan 2, 2026 | Restricted Stock Units |
| Kevin Lee Officer | Jan 2, 2026 | 21,500 | $146.16K | Jan 2, 2026 | Restricted Stock Units |
| Michael Charles Ferguson Hannay Officer | Jan 2, 2026 | 5,250 | $35.69K | Jan 2, 2026 | Restricted Stock Units |
| Alethia Young Officer | Jan 2, 2026 | 7,500 | $50.99K | Jan 2, 2026 | Restricted Stock Units |
See a number that looks wrong?